PMID- 8434556
OWN - NLM
STAT- MEDLINE
DCOM- 19930316
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 71
IP  - 6
DP  - 1993 Feb 25
TI  - The role of lipids and antioxidative factors for development of atherosclerosis. 
      The Probucol Quantitative Regression Swedish Trial (PQRST).
PG  - 15B-19B
AB  - The effect of probucol on the development of atherosclerosis is being 
      investigated in the Probucol Quantitative Regression Swedish Trial (PQRST). 
      Hypercholesterolemic patients are randomized to receive either probucol 0.5 g 
      twice daily or placebo in a double-blind manner, in combination with dietary 
      therapy and cholestyramine 8-16 g daily for a 3-year period. The primary endpoint 
      of the trial is the change in atheroma volume, assessed by annual quantitative 
      angiography involving 20-cm segments of the femoral artery. Data from the open 
      diet and prerandomization phase indicate that probucol added to dietary 
      intervention plus cholestyramine produced highly significant reductions in total 
      (-17%), low-density lipoprotein (LDL; -10%), and high-density lipoprotein (-30%) 
      cholesterol. From a subpopulation, LDL levels were isolated during different 
      stages of the prerandomization phase. LDL was exposed to the oxidant Cu2+ and 
      binding to fibroblasts as well as degradation by macrophages was measured. The 
      generation of thiobarbituric acid-reactive substances (TBARS) was also measured. 
      Probucol prevented degradation of copper-exposed LDL by macrophages and also 
      reduced the formation of TBARS, indicating that probucol protected LDL from 
      oxidation. After the trial concludes in December 1992, statistical models will be 
      used to investigate how much of the change in atherosclerosis is explained by 
      changes in lipoprotein concentrations and how much is explained by probucol's 
      antioxidative effects. Thus, other metabolic factors such as dietary intake and 
      circulating levels of lipid soluble vitamins and fatty acids that may modify the 
      possible antioxidative effects of probucol are also measured and will be related 
      to change in atherosclerosis.
FAU - Walldius, G
AU  - Walldius G
AD  - King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden.
FAU - Regnstrom, J
AU  - Regnstrom J
FAU - Nilsson, J
AU  - Nilsson J
FAU - Johansson, J
AU  - Johansson J
FAU - Schafer-Elinder, L
AU  - Schafer-Elinder L
FAU - Moelgaard, J
AU  - Moelgaard J
FAU - Hadell, K
AU  - Hadell K
FAU - Olsson, A G
AU  - Olsson AG
FAU - Carlson, L A
AU  - Carlson LA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Antioxidants)
RN  - 0 (Dietary Fats)
RN  - 0 (Lipids)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - P3CTH044XJ (Probucol)
SB  - IM
MH  - Aged
MH  - Antioxidants/*therapeutic use
MH  - Arteriosclerosis/blood/*drug therapy/*etiology
MH  - Cholesterol/blood
MH  - Dietary Fats/administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/blood/complications/*drug therapy
MH  - Lipids/*blood
MH  - Male
MH  - Probucol/*therapeutic use
MH  - Triglycerides/blood
EDAT- 1993/02/25 00:00
MHDA- 1993/02/25 00:01
CRDT- 1993/02/25 00:00
PHST- 1993/02/25 00:00 [pubmed]
PHST- 1993/02/25 00:01 [medline]
PHST- 1993/02/25 00:00 [entrez]
AID - 0002-9149(93)90140-8 [pii]
AID - 10.1016/0002-9149(93)90140-8 [doi]
PST - ppublish
SO  - Am J Cardiol. 1993 Feb 25;71(6):15B-19B. doi: 10.1016/0002-9149(93)90140-8.